|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.53 USD | -2.20% |
|
+0.10% | +27.56% |
| 07-17 | Xencor's Cancer Drug Study Selected for Oral Presentation at ESMO; Shares Rise | MT |
| 05-13 | Xencor, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 03:00 PM |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 1.45B | - | - | - | ||
| 55.2B | |||||
| 55.6B | |||||
| 23.51B | - | ||||
| 22.35B | - | ||||
| 20.6B |
- Stock Market
- Stocks
- XNCR Stock
- Charts Xencor, Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
